Bimzelx is the first and so far only approved therapy that selectively blocks IL-17A and IL-17A, according to UCB
10.1038/nrm2941 68 KampingaH
Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptor-targeted gold nanoparticles and liposomal cargo
Tight junctions, a collection of cytosolic and transmembrane proteins connected to the cytoskeleton, are key determinants of paracellular permeability[17]
EDTA is also widely reported to serve as a corneal penetration enhancer resulting from improved transcellular permeability, potentially through chelating Ca 2+ from epithelial and endothelial tight junctions [47, 48]
Additional examples of otoprotectants include, but are not limited to, Hes1/Hes5 SiRNA, Hes1 SiRNA, Hes5 SiRNA or other comparable modulators